Personalized Nutrition Market (By Product: Active Measurement, Standard Measurement; By Application: Standard Supplement, Disease-based; By End use: Direct-to-consumer, Wellness & Fitness Centers, Hospital & Clinics, Institutions, Food Delivery Services; By Dosage Forms: Tablets, Capsule, Powders, Liquids, Others; By Disease) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Personalized Nutrition Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Personalized Nutrition Market, by Product, 2023-2032
8.1.1. Active Measurement
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Standard Measurement
8.1.2.1. Market Revenue and Forecast (2020-2032)
9.1. Personalized Nutrition Market, by Application, 2023-2032
9.1.1. Standard Supplement
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Disease-based
9.1.2.1. Market Revenue and Forecast (2020-2032)
10.1. Personalized Nutrition Market, by End use, 2023-2032
10.1.1. Direct-to-consumer
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Wellness & Fitness Centers
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Hospital & Clinics
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Institutions
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Food Delivery Services
10.1.5.1. Market Revenue and Forecast (2020-2032)
11.1. Personalized Nutrition Market, by Dosage Forms, 2023-2032
11.1.1. Tablets
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Capsule
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Powders
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Liquids
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2020-2032)
12.1. Personalized Nutrition Market, by Disease, 2023-2032
12.1.1. Customized to the needs of consumer
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Fitness Goal Oriented Application
12.1.2.1. Market Revenue and Forecast (2020-2032)
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Forecast, by Application (2020-2032)
13.1.3. Market Revenue and Forecast, by End use (2020-2032)
13.1.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.1.5. Market Revenue and Forecast, by Disease (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
13.1.6.3. Market Revenue and Forecast, by End use (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.1.7. Market Revenue and Forecast, by Disease (2020-2032)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.8.2. Market Revenue and Forecast, by Application (2020-2032)
13.1.8.3. Market Revenue and Forecast, by End use (2020-2032)
13.1.8.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.1.8.5. Market Revenue and Forecast, by Disease (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Forecast, by Application (2020-2032)
13.2.3. Market Revenue and Forecast, by End use (2020-2032)
13.2.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.2.5. Market Revenue and Forecast, by Disease (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
13.2.6.3. Market Revenue and Forecast, by End use (2020-2032)
13.2.7. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.2.8. Market Revenue and Forecast, by Disease (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Application (2020-2032)
13.2.9.3. Market Revenue and Forecast, by End use (2020-2032)
13.2.10. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.2.11. Market Revenue and Forecast, by Disease (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Application (2020-2032)
13.2.12.3. Market Revenue and Forecast, by End use (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.2.13. Market Revenue and Forecast, by Disease (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Application (2020-2032)
13.2.14.3. Market Revenue and Forecast, by End use (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.2.15. Market Revenue and Forecast, by Disease (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Forecast, by Application (2020-2032)
13.3.3. Market Revenue and Forecast, by End use (2020-2032)
13.3.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.3.5. Market Revenue and Forecast, by Disease (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
13.3.6.3. Market Revenue and Forecast, by End use (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.3.7. Market Revenue and Forecast, by Disease (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
13.3.8.3. Market Revenue and Forecast, by End use (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.3.9. Market Revenue and Forecast, by Disease (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Application (2020-2032)
13.3.10.3. Market Revenue and Forecast, by End use (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.3.10.5. Market Revenue and Forecast, by Disease (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Application (2020-2032)
13.3.11.3. Market Revenue and Forecast, by End use (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.3.11.5. Market Revenue and Forecast, by Disease (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Forecast, by Application (2020-2032)
13.4.3. Market Revenue and Forecast, by End use (2020-2032)
13.4.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.4.5. Market Revenue and Forecast, by Disease (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
13.4.6.3. Market Revenue and Forecast, by End use (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.4.7. Market Revenue and Forecast, by Disease (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
13.4.8.3. Market Revenue and Forecast, by End use (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.4.9. Market Revenue and Forecast, by Disease (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Application (2020-2032)
13.4.10.3. Market Revenue and Forecast, by End use (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.4.10.5. Market Revenue and Forecast, by Disease (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Application (2020-2032)
13.4.11.3. Market Revenue and Forecast, by End use (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.4.11.5. Market Revenue and Forecast, by Disease (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Forecast, by Application (2020-2032)
13.5.3. Market Revenue and Forecast, by End use (2020-2032)
13.5.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.5.5. Market Revenue and Forecast, by Disease (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
13.5.6.3. Market Revenue and Forecast, by End use (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.5.7. Market Revenue and Forecast, by Disease (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Application (2020-2032)
13.5.8.3. Market Revenue and Forecast, by End use (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Dosage Forms (2020-2032)
13.5.8.5. Market Revenue and Forecast, by Disease (2020-2032)
14.1. DNA Fit
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Superior Supplement Manufacturing
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Metagenetics, Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Asiamerica, Ingredients
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Nutralliance, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Mixfix, Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Barrington Nutritionals
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Balchem Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Arizona Nutritional Supplements
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Maat Nutritionals
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample